title: Short-time splenic irradiation for splenomegaly.
abstract: BACKGROUND
  Splenic irradiation is routinely used in the supportive treatment of lymphoepithelial and hemopoietic diseases associated with splenomegaly. A new short-time irradiation schedule with conventional dosage (Group A: 2 Gy/fract.) was compared retrospectively with low-dose prolonged treatment schedules (Group B: < or = 1 Gy/fract.) to establish its tolerance and its efficacy in terms of relieving splenomegaly-associated symptoms.
  
  
  METHODS
  Between 12/1996 and 3/2002 49 patients (6 with CLL, 14 with CML, 6 with NHL, 16 with MPD, 6 with OMF and 1 with AML) underwent 85 treatment courses (13 courses low-dose prolonged treatment and 72 courses short-time treatment).The spleens had been exposed to pretreatment doses of 3-70 Gy (mean 20.75 Gy). Splenic size was 12-35 cm (mean 22.76 cm). One treatment was done with 60Co. 9-20 MeV electron beams were used in 23 treatments and 6 MV photons in 61 treatments. Blood counts were monitored daily. Clinical improvement (pain relief, improvement of splenomegaly-associated symptoms), spleen volume reduction and effects on blood counts were evaluated and documented at the end of the treatment.
  
  
  RESULTS
  Of the 85 treated patients, 55 (Group A: 47/72, Group B: 8/13) showed a > 10% reduction of spleen volume and 62 (Group A: 57/72, Group B: 5/13) clinical improvement. 15 of 49 patients underwent multiple irradiation (2-8 courses) without clinical or hematologic complications. The intervals between the courses were 2-19 months. Rapid response in terms of reduction in splenic size in 23 patients permitted field reduction during treatment. Significant hematologic abnormalities were absent throughout.
  
  
  CONCLUSIONS
  The short-time treatment schedule ensured a rapid response with relief of pain and improvement of gastrointestinal and pulmonary symptoms at an overall treatment time shorter than that of low-dose prolonged treatment schedules. No differences in terms of hematologic abnormalities were found between single doses of 2 Gy and < or = 1 Gy.
authors.affiliation: Institute of Radio-Oncology, Kaiser-Franz-Josef Hospital, Vienna, Austria. annemarie.schratter@kfj.magwien.gv.at
authors.forename: A U
authors.initials: AU
authors.lastname: Schratter-Sehn
authors.forename: M
authors.initials: M
authors.lastname: Cerveny
authors.forename: H
authors.initials: H
authors.lastname: Simmel
authors.forename: E
authors.initials: E
authors.lastname: Schlögl
authors.forename: A
authors.initials: A
authors.lastname: Schratter
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001772:Blood Cell Count; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D007938:Leukemia / Q000473:pathology / Q000532:radiotherapy*; D015182:Lymphatic Irradiation; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013163:Splenomegaly / Q000532:radiotherapy*; D016896:Treatment Outcome